Rising prevalence of genetic respiratory disorders, expanding healthcare infrastructure, and strong R&D investments fuel sustained market growth worldwide.Austin, Texas, Jan. 13, 2026 (GLOBE NEWSWIRE) ...
The Phase 1/2 trial is a first-in-human, open-label, multi-national study designed to evaluate the safety, tolerability, and efficacy of TSRA-196 in adults with AATD. Trial participants will receive a ...
Investor's Business Daily on MSN
Beam soars 22% as FDA signs off on its ambitious gene-editing plan
Beam stock launched Monday after the company reached a deal with the Food and Drug Administration for its gene-editing drug, ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Least-squares mean percent differences in serum Z-AAT ...
Alpha-1 antitrypsin deficiency (AATD) is a hereditary condition characterised by the misfolding of the alpha-1 antitrypsin (AAT) protein, resulting in its hepatic accumulation and compromised protease ...
Kamada shows strong Q2 2023 financials with 59% YoY revenue jump, led by KEDRAB sales, and solid liquidity. Despite growth, AAT deficiency project introduces uncertainty due to weak Phase 2 results, ...
Alpha-1 antitrypsin deficiency, AATD, is an inherited disease affecting the lung, liver, and, rarely, skin. Alpha-1 antitrypsin, AAT, is a protease inhibitor of the proteolytic enzyme elastase.
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Augmentation therapy increased survival in patients with ...
Boosting levels of a deficient protein has clear survival benefits for people with the genetic condition alpha-1 antitrypsin deficiency (AATD), according to new research led by RCSI University of ...
PITTSBURGH, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development, and ...
National Jewish Health researchers with the Advanced Diagnostic Laboratories have developed a molecular diagnostic test capable of accurately diagnosing a major genetic cause of chronic obstructive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback